Latest GENERAL ATLANTIC LLC Stock Portfolio
GENERAL ATLANTIC LLC Performance:
2025 Q2: -5.41%YTD: 7.04%2024: 15.4%
Performance for 2025 Q2 is -5.41%, and YTD is 7.04%, and 2024 is 15.4%.
About GENERAL ATLANTIC LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, GENERAL ATLANTIC, L.P. reported an equity portfolio of $3.6 Billions as of 30 Jun, 2025.
The top stock holdings of GENERAL ATLANTIC, L.P. are , , ALHC. The fund has invested 20% of it's portfolio in DLOCAL and 18.3% of portfolio in CHIME.
The fund managers got completely rid off IMMUNOCORE (IMCR), ACELYRIN and WISH (WISH) stocks. They significantly reduced their stock positions in ALIGNMENT HEALTHCARE (ALHC) and XP, INC (XP). GENERAL ATLANTIC, L.P. opened new stock positions in CHIME. The fund showed a lot of confidence in some stocks as they added substantially to AKERO THERAPEUTICS (AKRO).
The top stock holdings of GENERAL ATLANTIC, L.P. are , , ALHC. The fund has invested 20% of it's portfolio in DLOCAL and 18.3% of portfolio in CHIME.
The fund managers got completely rid off IMMUNOCORE (IMCR), ACELYRIN and WISH (WISH) stocks. They significantly reduced their stock positions in ALIGNMENT HEALTHCARE (ALHC) and XP, INC (XP). GENERAL ATLANTIC, L.P. opened new stock positions in CHIME. The fund showed a lot of confidence in some stocks as they added substantially to AKERO THERAPEUTICS (AKRO).
GENERAL ATLANTIC LLC Annual Return Estimates Vs S&P 500
Our best estimate is that GENERAL ATLANTIC, L.P. made a return of -5.41% in the last quarter. In trailing 12 months, it's portfolio return was 22.07%.
New Buys
| Ticker | $ Bought |
|---|---|
| chime | 662,894,000 |
| webull | 85,490,700 |
| alumis | 3,892,590 |
New stocks bought by GENERAL ATLANTIC LLC
Additions
| Ticker | % Inc. |
|---|---|
| akero therapeutics | 9.55 |
Additions to existing portfolio by GENERAL ATLANTIC LLC
Reductions
| Ticker | % Reduced |
|---|---|
| alignment healthcare | -27.87 |
| xp, inc | -13.84 |
GENERAL ATLANTIC LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| acelyrin | -6,657,460 |
| immunocore | -37,434,200 |
| wish | -4,255,120 |
GENERAL ATLANTIC LLC got rid off the above stocks
Sector Distribution
GENERAL ATLANTIC, L.P. has about 59.5% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 59.5 |
| Healthcare | 30.4 |
| Technology | 8 |
| Consumer Defensive | 2.1 |
Market Cap. Distribution
GENERAL ATLANTIC, L.P. has about 1.5% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 59.5 |
| SMALL-CAP | 30.9 |
| MID-CAP | 8 |
| LARGE-CAP | 1.5 |
Stocks belong to which Index?
About 35.4% of the stocks held by GENERAL ATLANTIC, L.P. either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 64.6 |
| RUSSELL 2000 | 35.4 |
GENERAL ATLANTIC LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of GENERAL ATLANTIC LLC
GENERAL ATLANTIC, L.P. has 15 stocks in it's portfolio. About 97.4% of the portfolio is in top 10 stocks. ALHC proved to be the most loss making stock for the portfolio. AKRO was the most profitable stock for GENERAL ATLANTIC, L.P. last quarter.
Last Reported on: 14 Aug, 2025| Ticker | Namesorted descending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| dlocal | 19.97 | 63,906,700 | 724,702,000 | unchanged | 0.00 | |||
| chime | 18.26 | 19,208,800 | 662,894,000 | new | ||||
| ALHC | alignment healthcare | 16.97 | 43,993,300 | 615,906,000 | reduced | -27.87 | ||
| XP | xp, inc | 14.20 | 25,517,700 | 515,458,000 | reduced | -13.84 | ||
| AKRO | akero therapeutics | 8.43 | 5,733,990 | 305,966,000 | added | 9.55 | ||
| ALKT | alkami | 8.01 | 9,645,320 | 290,710,000 | unchanged | 0.00 | ||
| PHVS | pharvaris | 3.65 | 7,531,250 | 132,550,000 | unchanged | 0.00 | ||
| CNTA | centessa pharmaceuticals | 3.50 | 9,681,820 | 127,219,000 | unchanged | 0.00 | ||
| webull | 2.36 | 7,148,050 | 85,490,700 | new | ||||
| EWCZ | european wax center | 2.03 | 13,110,500 | 73,812,100 | unchanged | 0.00 | ||
| RPRX | royalty pharma | 1.49 | 1,500,000 | 54,045,000 | unchanged | 0.00 | ||
| riskified | 0.73 | 5,325,000 | 26,571,700 | unchanged | 0.00 | |||
| adagene | 0.21 | 3,825,950 | 7,460,610 | unchanged | 0.00 | |||
| alumis | 0.11 | 1,297,530 | 3,892,590 | new | ||||
| GROV | grove collaborative | 0.08 | 2,474,860 | 2,846,090 | unchanged | 0.00 | ||
| IMCR | immunocore | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| WISH | wish | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| acelyrin | 0.00 | 0.00 | 0.00 | sold off | -100 | |||
